METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN PATIENTS SUFFERING FROM LUNG CANCER Russian patent published in 2014 - IPC G01N33/52 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for the prediction of integrated clinical effectiveness in the patients suffering from lung cancer in an early postoperative period. Substance of the invention consists in the fact that a patient's blood plasma α-1-proteinase inhibitor is measured for the first postoperative day and perioperative autochemoimmunotherapy. If observing an increase of the derived value by 28% and more as related to the common norm, the treatment is predicted to be effective, while a variation of less than 28%, no variations, or a decrease as compared to the norm show ineffective treatment. A specificity of the method for the instant prediction of integrated clinical effectiveness at the initial stages is 80.9%, and for the prediction of no effectiveness - 97%.

EFFECT: using the method provides high specificity, enabling instant objective evaluation of integrated clinical effectiveness at the initial stages, carrying out cito analysis, as well as prescribing well-timed adequate therapeutic measures or replacing the treatment.

4 ex